Journal article
Treatment of CIDP
- Abstract:
- Chronic inflammatory demyelinating polyneuropathy is a disabling but treatable disorder. However, misdiagnosis is common, and it can be difficult to optimise its treatment. Various agents are used both for first and second line. First-line options are intravenous immunoglobulin, corticosteroids and plasma exchange. Second-line therapies may be introduced as steroid-sparing agents or as more potent escalation therapy. It is also important to consider symptomatic treatment of neuropathic pain and non-pharmacological interventions. We discuss the evidence for the various treatments and explain the practicalities of the different approaches. We also outline strategies for monitoring response and assessing the ongoing need for therapy.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 202.8KB, Terms of use)
-
- Publisher copy:
- 10.1136/pn-2021-002991
Authors
- Publisher:
- BMJ Publishing Group
- Journal:
- Practical Neurology More from this journal
- Volume:
- 23
- Issue:
- 1
- Pages:
- 46-53
- Place of publication:
- England
- Publication date:
- 2022-09-15
- Acceptance date:
- 2022-07-10
- DOI:
- EISSN:
-
1474-7766
- ISSN:
-
1474-7758
- Pmid:
-
36109154
- Language:
-
English
- Keywords:
- Pubs id:
-
1279840
- Local pid:
-
pubs:1279840
- Deposit date:
-
2023-02-02
Terms of use
- Copyright holder:
- Fehmi et al
- Copyright date:
- 2023
- Rights statement:
- © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from BMJ Publishing Group at: http://dx.doi.org/10.1136/pn-2021-002991
If you are the owner of this record, you can report an update to it here: Report update to this record